Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus Price Target from Brokerages

Shares of Mural Oncology PLC (NASDAQ:MURA) have earned an average rating of “Hold” from the five brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $12.00.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mural Oncology in a research report on Monday, December 8th.

Mural Oncology Price Performance

Shares of MURA opened at $2.04 on Wednesday. The firm has a market capitalization of $35.38 million, a PE ratio of -0.29 and a beta of 2.93. The firm has a 50-day moving average price of $2.07 and a 200 day moving average price of $2.17. Mural Oncology has a 52-week low of $0.95 and a 52-week high of $4.74.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.38. On average, equities analysts expect that Mural Oncology will post -7.54 EPS for the current year.

Institutional Investors Weigh In On Mural Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of MURA. Armistice Capital LLC grew its stake in shares of Mural Oncology by 1.3% in the 1st quarter. Armistice Capital LLC now owns 1,722,000 shares of the company’s stock worth $2,170,000 after purchasing an additional 22,000 shares during the last quarter. Emerald Mutual Fund Advisers Trust bought a new stake in Mural Oncology during the second quarter worth approximately $192,000. Quadrature Capital Ltd acquired a new position in Mural Oncology in the second quarter worth approximately $98,000. F m Investments LLC bought a new position in shares of Mural Oncology in the second quarter valued at $192,000. Finally, Diametric Capital LP acquired a new stake in shares of Mural Oncology during the 2nd quarter valued at $864,000. 80.21% of the stock is currently owned by institutional investors.

About Mural Oncology

Mural Oncology, Inc (NASDAQ: MURA) is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for cancer. The company’s research emphasizes targeting the tumor microenvironment and stromal resistance mechanisms to enhance the efficacy of existing and novel oncology agents.

Mural’s pipeline features small-molecule programs designed to inhibit signaling pathways involved in tumor growth and extracellular matrix remodeling. Its lead candidates are advancing through early-phase clinical trials in various solid tumors, leveraging translational biology tools such as patient-derived models and molecular profiling to guide drug discovery and patient selection.

Headquartered in San Mateo, California, Mural Oncology conducts research and development in the United States and collaborates with academic institutions and industry partners to support global clinical development.